

Outcomes by Body Mass Index (BMI) in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin

Vazquez JA,¹ Flanagan S,² Pappas P,³ Thompson GR III,⁴ Sandison T,² Honore PM³

¹Augusta University, August, GA, USA; ²Cidara Therapeutics, Inc., San Diego, CA, USA; ³Univ of Alabama at Birmingham, Birmingham, AL, USA;

⁴Univ of California Davis Medical Center, Sacramento, CA, USA; Brugmann Univ Hospital, Brussels, Belgium

Jose A. Vazquez, MD, FIDSA, FACP
jvazquez@augusta.edu
706-721-1244

INTRODUCTION

- A 'silent epidemic' of antifungal underdosing in the treatment of invasive disease in the critically ill may also affect special populations, such as the obese[1]
- Body size is an important variable affecting drug exposure
- Pharmacokinetic (PK) models of antifungal dosing suggest size-based adjustments to achieve target drug exposure
- Rezafungin is a novel echinocandin distinguished by a PK profile that includes long half-life, extensive tissue distribution, and front-loaded drug exposure, lending to once-weekly (QWk) dosing and antifungal efficacy [2,3]
- Rezafungin is currently in Phase 3 development for treatment of candidemia and invasive candidiasis (IC) [ReSTORE; NCT03667690] and for prevention of invasive fungal disease caused by *Candida*, *Aspergillus*, and *Pneumocystis* in blood and marrow transplant recipients [ReSPECT; NCT04368559]
- A sub-analysis of results from the Phase 2 STRIVE trial of rezafungin QWk in the treatment of candidemia and/or IC [NCT02734862] compared with caspofungin once daily (Figure 1) was conducted to evaluate outcomes based on patient BMI

Figure 1. Treatment Groups of the Phase 2 STRIVE Trial

Group	Dose Regimen	Dose Schedule
RZF Group 1	IV rezafungin 400 mg QWk	On Days 1 and 8
RZF Group 2	IV rezafungin 400 mg on Week 1, followed by 200 mg QWk*	Optional doses(s) on Day 15 (and on Day 22 for IC)
CAS	IV caspofungin 70 mg on Day 1, followed by 50 mg QD (with optional step-down to oral fluconazole)	Once daily for up to 21 days for candidemia or 28 days for IC ≥ candidemia

*Rezafungin dosing regimen in Phase 3.

CAS=caspofungin; RZF-rezafungin; QD=once daily; QWk=once weekly

METHODS

- For this subanalysis, data were stratified by BMI categories (<30 kg/m² and ≥30 kg/m²) and assessed for:
 - Safety
 - Treatment-emergent adverse events [TEAEs] by treatment group
 - Efficacy
 - Overall response (resolution of clinical signs of infection and mycological eradication)
 - Mycological response
 - Investigator assessment of clinical response
 - PK
 - Area under the curve (AUC) from RZF-treated patients in the first part of the trial

RESULTS

- Mean BMI values: rezafungin Group 1, 26.9 kg/m²; rezafungin Group 2 and caspofungin arms, 26.8 kg/m²

Safety

- TEAE rates were generally similar between categories (Table 1), with no concerning safety trends

Table 1. Summary of TEAEs by BMI Category (<30 mg/kg² vs ≥30 mg/kg²) from the STRIVE Trial (Safety Population)

TEAE	n (%)					
	BMI <30 kg/m ²			BMI ≥30 kg/m ²		
	RZF Grp 1 N=59	RZF Grp 2 N=37	CAS N=51	RZF Grp 1 N=21	RZF Grp 2 N=15	CAS N=17
At least 1 TEAE	51 (86.4)	33 (89.2)	42 (82.4)	19 (90.5)	15 (100)	13 (76.5)
Study drug-related TEAE	4 (6.8)	5 (13.5)	6 (11.8)	3 (14.3)	1 (6.7)	3 (17.6)
TEAE leading to study drug discontinuation	4 (6.8)	1 (2.7)	4 (7.8)	2 (9.5)	0	0

RESULTS (cont'd)

Efficacy

- Efficacy outcomes at Day 14 were similar between BMI categories (Table 2)

Table 2. Efficacy Outcomes by BMI Category (<30 kg/m² vs ≥30 kg/m²) in STRIVE (mITT Population)

Outcomes at Day 14	n (%)					
	BMI <30 kg/m ²			BMI ≥30 kg/m ²		
	RZF Grp 1 N=57	RZF Grp 2 N=34	CAS N=48	RZF Grp 1 N=18	RZF Grp 2 N=11	CAS N=13
Overall Response	34 (59.6)	26 (76.5)	32 (66.7)	11 (61.1)	8 (72.7)	9 (69.2)
Mycological Response	37 (64.9)	26 (76.5)	33 (68.8)	12 (66.7)	8 (72.7)	9 (69.2)
Investigator Assessment of Clinical Cure	40 (70.2)	28 (82.4)	33 (68.8)	12 (66.7)	8 (72.7)	10 (76.9)

CONCLUSIONS

- Rezafungin safety, efficacy, and PK in STRIVE was consistent across BMI categories
- These results suggest that rezafungin dose adjustments in obese patients are not necessary
- These findings contribute to the evaluation of rezafungin in a range of patient populations and its further development

REFERENCES

- Pea F and RE Lewis. *J Antimicrob Chemother.* 2018;73(suppl_1):i33-i43. <https://doi.org/10.1093/jac/dkx447>
- Sandison T, Ong V, Lee J, Thye D. *Antimicrob Agents Chemother.* 2017;61(2):e01627-16. doi:10.1128/AAC.01627-16
- Lakota EA, Bader JC, Ong V, et al. *Antimicrob Agents Chemother.* 2017;61(11):e00758-17. doi:10.1128/AAC.00758-17

ACKNOWLEDGMENTS


Cidara Therapeutics sponsored and funded the STRIVE trial and had a role in the trial design, data collection, and analysis, and in the decision to submit these data for presentation. Medical writing assistance was provided by T. Chung (Scribant Medical) with funding from Cidara.

RESULTS (cont'd)

PK

- Following one dose of rezafungin 400 mg (Week 1), AUC ranges by BMI category overlapped (Figure 2)
- AUC values for BMI ≥30 kg/m² group were ~20% lower vs in the <30 kg/m² group (mean [SD] AUC: 615 [104] µg•h/mL vs 741 [194] µg•h/mL, respectively)

Figure 2. Rezafungin AUC Following One 400-mg Dose at Week 1 by BMI Category (<30 kg/m² vs ≥30 kg/m²)



^aAUC data shown for patients with PK data available for this analysis.